alefacept

Home
Ligands
alefacept

GtoPdb Ligand ID: 6787

Synonyms: Amevive® | BG 9273 | BG 9712 | BG-9273 | BG-9712 | Lfa3Tip

alefacept is an approved drug (FDA (2003))

Compound class: Peptide or derivative

Comment: This is a fusion protein of the CD2 ligand (CD58/LFA3, lymphocyte function associated antigen 3) linked to the Fc domain of IgG1. The construct is called LFA3TIP in [2].

References
1. da Silva AJ, Brickelmaier M, Majeau GR, Li Z, Su L, Hsu YM, Hochman PS. (2002) Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J Immunol, 168 (9): 4462-71. [PMID:11970990]
2. Miller GT, Hochman PS, Meier W, Tizard R, Bixler SA, Rosa MD, Wallner BP. (1993) Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med, 178 (1): 211-22. [PMID:7686212]
3. Mitchell P. (2002) First biotech drug to treat psoriasis. Nat Biotechnol, 20 (7): 640-1. [PMID:12089534]

References

1. da Silva AJ, Brickelmaier M, Majeau GR, Li Z, Su L, Hsu YM, Hochman PS. (2002)
Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells.
J Immunol, 168 (9): 4462-71. [PMID:11970990]

2. Miller GT, Hochman PS, Meier W, Tizard R, Bixler SA, Rosa MD, Wallner BP. (1993)
Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses.
J Exp Med, 178 (1): 211-22. [PMID:7686212]

3. Mitchell P. (2002)
First biotech drug to treat psoriasis.
Nat Biotechnol, 20 (7): 640-1. [PMID:12089534]